Anaphylaxis is an acute, life-threatening systemic allergic reaction that may have a wide range of clinical manifestations.[@bib1] Some of those signs and symptoms are similar to those that happen during the acute respiratory distress caused by the novel coronavirus disease 2019 (COVID-19).[@bib2]

A 74-year-old woman with a history of hypertension and bronchial asthma presented to the emergency department (ED) with a 3-day history of malaise, subjective fever, dry cough, and diarrhea. On admission, her temperature was 36.9°C with a pulse rate of 99 bpm, blood pressure of 127/83 mm Hg, and oxygen saturation of 93% on ambient air. Laboratory test results indicated mild lymphopenia (lymphocyte count of 1.0 × 10^9^/L), and the C-reactive protein level was elevated at 55 mg/L. Chest radiography showed no consolidations. COVID-19 was diagnosed based on reverse transcription--polymerase chain reaction test results, which detected severe acute respiratory syndrome coronavirus 2. Per the hospital\'s COVID-19 protocol, the patient was discharged with instructions for isolation and a dose of cefixime 400 mg daily as an empirical antibiotic to prevent potential superinfection. She had tolerated other β-lactams in the past (penicillin, amoxicillin), but did not recall taking cephalosporins.

A few hours later, the patient presented to the ED again because of a sudden onset of dyspnea. On examination, the blood pressure was 90/55 mm Hg, pulse rate was 119 bpm, and oxygen saturation was 80%. She also had hives, erythema, systemic pruritus, and a swollen tongue. The episode started 20 minutes after she took the first dose of cefixime and progressed from the initial mild pruritus of her palms and soles. Laboratory test results indicated moderate lymphopenia (0.4 × 10^9^/L) and elevated D-dimer (12.8 mg/L). Because of high D-dimer levels, the patient underwent a pulmonary angiogram, which turned out normal, ruling out pulmonary embolism.

She received methylprednisolone, dexchlorpheniramine, inhaled salbutamol and oxygen, and experienced full recovery in 2 hours, with an improvement of vital signs, including blood pressure (127/76 mm Hg) and oxygen saturation (97%). An electrocardiogram showed normal rhythm at a rate of 64. Yet, a cytokine release syndrome was suspected, and the patient was admitted to the COVID-19 unit and started treatment with hydroxychloroquine, lopinavir and ritonavir. However, other markers were at normal levels (ferritin 199 μg/L), and D-dimer levels decreased to 2.7 mg/L in 12 hours, rapidly reaching normal levels in 2 days ([Fig 1](#fig1){ref-type="fig"} ). The baseline serum tryptase levels on arrival at the ED were elevated (65.8 μg/L), but after 10 days, the levels decreased to within the reference range (4.18 μg/L).Figure 1Evolution of D-dimer levels. ICU, intensive care unit.

The patient remained in stable condition until day 12 when she suddenly worsened with the reappearance of fever and hypoxemia. Chest radiography showed left middle-lobe pneumonia; thus, treatment with methylprednisolone was started. She was admitted to the intensive care unit on day 13. Coinciding with this deterioration, her D-dimer levels increased up to 1.2 mg/L ([Fig 1](#fig1){ref-type="fig"}), and so did other inflammatory markers (ferritin, 2186 μg/L). Despite intubation, anticoagulation, and vasoactive drug therapy, the patient died after 9 days.

This case indicates how anaphylaxis may mimic symptoms caused by SARS-CoV-2. Cytokine release syndrome has been described in patients with COVID-19, which present with sudden-onset dyspnea, hypoxemia, and increased D-dimer levels[@bib2]; a variety of skin lesions have also been reported,[@bib3] including urticaria.[@bib4] However, these signs and symptoms may also be present in patients with anaphylaxis, including elevated D-dimer levels.[@bib5] Therefore, the differential diagnosis between these 2 conditions can be challenging. In this patient, the presence of typical anaphylaxis symptoms (itching of palms and soles) and its acute development after exposure to a likely allergen, and also an elevated serum tryptase were key in the diagnosis of anaphylaxis.[@bib1] Curiously, she had much higher D-dimer levels during anaphylaxis than when she suffered more severe signs from COVID-19. Although there has been no experience with COVID-19, other viral infections are known to act as cofactors, increasing the severity of anaphylaxis.[@bib6] This might have contributed to the severity of anaphylaxis in this particular case. Finally, cefixime allergy could not be confirmed owing to the fatal outcome. However, the temporal sequence strongly suggests that cefixime was the trigger of the anaphylaxis.[@bib7]
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